Alterity Therapeutics Limited
PRNAF
$0.40
$0.0514.29%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 2.39M | 3.34M | 4.27M | 3.87M | 3.49M |
| Total Revenue | 2.39M | 3.34M | 4.27M | 3.87M | 3.49M |
| Cost of Revenue | 177.40K | 141.40K | 105.30K | 93.60K | 82.60K |
| Gross Profit | 2.21M | 3.20M | 4.16M | 3.78M | 3.41M |
| SG&A Expenses | 7.07M | 5.90M | 4.73M | 4.13M | 3.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 189.00K | 166.90K | 144.80K | 100.40K | 56.70K |
| Total Operating Expenses | 19.31M | 17.49M | 15.63M | 14.26M | 12.99M |
| Operating Income | -16.92M | -14.15M | -11.36M | -10.39M | -9.50M |
| Income Before Tax | -15.70M | -12.54M | -9.37M | -8.57M | -7.85M |
| Income Tax Expenses | 76.00K | 79.90K | 83.40K | 63.20K | 43.10K |
| Earnings from Continuing Operations | -15.78 | -12.62 | -9.45 | -8.64 | -7.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.78M | -12.62M | -9.45M | -8.64M | -7.89M |
| EBIT | -16.92M | -14.15M | -11.36M | -10.39M | -9.50M |
| EBITDA | -16.91M | -14.15M | -11.35M | -10.37M | -9.48M |
| EPS Basic | -0.07 | -0.06 | -0.05 | -0.06 | -0.07 |
| Normalized Basic EPS | -0.05 | -0.04 | -0.04 | -0.04 | -0.05 |
| EPS Diluted | -0.08 | -0.06 | -0.05 | -0.06 | -0.07 |
| Normalized Diluted EPS | -0.05 | -0.04 | -0.04 | -0.04 | -0.05 |
| Average Basic Shares Outstanding | 841.98M | 774.19M | 706.40M | 609.08M | 511.75M |
| Average Diluted Shares Outstanding | 841.98M | 774.19M | 706.40M | 609.08M | 511.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |